Claims for Patent: 5,128,451

Summary for Patent: 5,128,451

Title:	Protein V:AIgG binding factor
Abstract:	A novel bacterial proteinaceous immunoglobulin G receptor is disclosed. The proteinaceous factor binds all four subclasses of human IgG, as well as rabbit, swine, equine, bovine, sheep, and goat IgG. The proteinaceous factor is obtained from biologically pure cultures of Gardnerella vaginalis such as those having the identifying characteristics of ATCC Deposit No. 55195.
Inventor(s):	Allen; John W. (Chapel Hill, NC)
Assignee:
Application Number:	07/733,219
Patent Claims:	1. A purified proteinaceous factor obtained from Gardnerella vaginalis, which factor is a receptor for the Fc region of human IgG, which factor binds human IgG.sub.1, human IgG.sub.2, human IgG.sub.3, and human IgG.sub.4, and which factor resolves into one major band on non denaturing gels at about 96,000 daltons. 2. The proteinaceous factor of claim 1 immobilized on an inert solid support. 3. The proteinaceous factor of claim 1 labeled with a detectable group selected from the group consisting of radioisotopes, enzymes, and electron dense ligands. 4. The proteinaceous factor of claim 1 labeled with a radioisotope selected from the group consisting of .sup.125 I, .sup.131 I, .sup.3 H, .sup.14 C, and .sup.35 S. 5. The proteinaceous factor of claim 1 labeled with an enzyme selected from the group consisting of lactoperoxidase, horseradish peroxidase, alkaline phosphatase, and glucose oxidase. 6. The proteinaceous factor of claim 1 labeled with an electron dense ligand selected from the group consisting of ferritin, gold, and horseradish peroxidase. 7. A purified proteinaceous factor having the following identifying characteristics: (a) is isolated from Gardenerella vaginalis; (b) reacts with the Fc protion of human immunoglobulin g; (c) possesses affinity for all four subclasses of human IgG; (d) possesses non-specific affinity for a broad range of mammalian IgG, including rabbit, swine, horse, bovine, sheep and goat; (e) has a molecular weight of about 96,000 on non-denaturing gels; and (f) demonstrates inhibited activity in the presence of Proteinase K.

Details for Patent 5,128,451

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2040-01-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2040-01-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2040-01-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	02/07/2013		2040-01-28
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	09/17/2009		2040-01-28
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	02/06/2017		2040-01-28